Bonfanti P, Valsecchi L, Parazzini F,Carradori S, Pusterla L, Fortuna P, Timillero L, Alessi F, Ghiselli G, Gabbuti A, Di Cintio E, Martinelli C, Faggion I, Landonio S, Quirino T. "Incidence of adverse reactions in HIV-patients treated with protease inhibitors: a cohort study" J Acquir Immune Defic Syndr 2000; 23: 236 - 245.

Quirino T, Niero F, Ricci E, Pusterla L, Carradori S, Gabbuti A, Iemoli E, Landonio S, Faggion I, Bonfanti P. "HAART tolerability: post-exposure prophylaxis in healthcare workers versus treatment in HIV infected patients." Antivir Ther 2000; 5: 195-197

Bonfanti P, Valsecchi L, Parazzini F, Carradori S, Pusterla L, Fortuna P, Timillero L, Alessi F, Ghiselli G, Gabbuti A, Ricci E, Martinelli C, Faggion I, Landonio S, Quirino T. "Relazione di causalità delle reazioni averse a farmaci: un'esperienza nell'utilizzo degli inibitori della proteasi di HIV" Clin Ter 2000; 151: 411-415

Bonfanti P, Gabbuti A, Carradori S, Pusterla L, Parazzini F, Landonio S, Quirino T. "Osteonecrosis in protease inhibitor-treated patients" Orthopedics 2001; 24: 271 - 272

Bonfanti P, Landonio S, Ricci E, Martinelli E, Fortuna P, Faggion I, Quirino T "Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy" J Acquir Immune Defic Syndr 2001; 27: 316 - 318

Bonfanti P, Landonio S, Ricci E, Martinelli E, Fortuna P, Faggion I, Quirino T for the CISAI study group"Predictors of protease inhibitor-associated adverse events"Biomed Pharmacother 2001; 55: 321 -323

Bonfanti P, Valsecchi L, Ricci E, Carradori S, Pusterla L, Fortuna P, Timillero L, Miccolis S, Magnani C, Gabbuti A, Parazzini F, Cinelli R, Faggion I, Landonio S, Quirino T, Vigevani GM. "I diversi profili di tollerabilità degli Inibitori della proteasi: lo studio CISAI" Giorn It Mal Inf 2001; 7 (S2): S13- S17

Bonfanti P, Ricci E, Landonio S, Valsecchi L, Timillero L, Faggion I, Quirino T for the CISAI study group. "Predictors of protease inhibitor-associated adverse events." Biomed Pharmacother 2001; 55: 321 -323

Timillero L, Bonfanti P, Ricci E, Valsecchi L, Carradori S, Pusterla L, Fortuna P, Miccolis S, Magnani C, Gabbuti A, Parazzini F, Cinelli R, Faggion I, Landonio S, Quirino T, Vigevani GM. "I fattori di rischio per lo sviluppo della lipodistrofia nella coorte CISAI" Giorn It Mal Inf 2001; 7 (S2): S65 - S67

Landonio S, Quirino T, Pelucchi A, Magni C, Coen M, Porretta T, Faggion I, Bonfanti P, Vigevani GM. ".Bilateral carotid stenosis in young female HIV-patient treated with HAART" AIDS 2002; 16: 2225 - 2227

Bonfanti P, Gulisano C, Ricci E, Timillero L, Valsecchi L, Carradori S, Pusterla L, Fortuna P, Miccolis S, Magnani C, Gabbuti A, Parazzini F, Martinelli C, Faggion I, Landonio S, Quirino T, Vigevani GM. "Risk factors for lipodystrophy in the CISAI cohort" Biomed Pharmacother 2003; 57: 422-427

Quirino T, Bongiovanni M, Ricci E, Chebat E, Carradori S, Martinelli C, Valsecchi L, Landonio S, Bini T, Bonfanti P. "Hypothyroidism in HIV-infected patients who have or have not received HAART" Clin Infect Dis. 2004;38(4):596-7

Landonio S, Quirino T, Bonfanti P, Gabris A, Boccassini L, Gulisano C, Vulpio L, Ricci E, Carrabba M, Vigevani G.M. "Osteopenia and osteoporosis in HIV+ patients, untreated or receiving HAART" Biomed Pharmacother 2004; 58: 505-8.

Bonfanti P, Martinelli C, Ricci E, Carradori S, Parruti G, Armignacco O, Magnani C, Quirino T; CISAI Group (Italian Coordinators for the Study of Allergies HIV Infection). An Italian approach to postmarketing monitoring: preliminary results from the SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals) project on the safety of lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2005; 39:317-20

Bonfanti P, Ricci E, Penco G, Orofino G, Bini T, Sfara C, Miccolis S, Cristina G, Quirino T; CISAI Study Group. Low incidence of hepatotoxicity in a cohort of HIV patients treated with lopinavir/ritonavir. AIDS. 2005 Sep 2;19(13):1433-4

Bonfanti P, Ricci E, de Socio G, Zeme D, Carradori S, Penco G, Parruti G, Grosso C, Madeddu G, Vichi F, Bini T, Martinelli C, Melzi S, Quirino T; CISAI Study Group. Metabolic syndrome: a real threat for HIV-positive patients?: Results from the SIMONE study. J Acquir Immune Defic Syndr. 2006 May;42(1):128-31

Madeddu G, Quirino T, Carradori S, Ricci E, Grosso C, Penco G, De Socio G, Rosella E, Palvarini L, Marconi P, Melzi S, Mura MS e Bonfanti P per il gruppo CISAI. Renal toxicity in HIV-infected patients receiving HAART including tenofovir. Infez Med 2006; 3: 125-134.

Bonfanti P, Giannattasio C, Ricci E, Facchetti R, Rosella E, Franzetti M, Cordier L, Pusterla L, Bombelli M, Sega R, Quirino T, Mancia G. HIV and Metabolic Syndrome: a comparison with the general population. J Acquir Immune Defic Syndr 2007; 45: 426-31.

De Socio GV, Bonfanti P, Ricci E, Orofino G, Madeddu G, Penco G, Gianelli E, Martinelli C, Carradori S, Quirino T, Rizzardini G; for the CISAI Study Group. Cholesterol levels in HIV-HCV infected patients treated with lopinavir/r: Results from the SCOLTA project. Biomed Pharmacother. 2008; 62: 16-20.

Madeddu G, Bonfanti P, De Socio GV, Carradori S, Grosso C, Marconi P, Penco G, Rosella E, Miccolis S, Melzi S, Mura MS, Landonio S, Ricci E, Quirino T, for the CISAI Group. Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project. Biomed Pharmacother; 2008; 62: 6-11.

De Socio GV, Parruti G, Quirino T, Ricci E, Schillaci G, Adriani B, Marconi P, Franzetti M, Martinelli C, Vichi F, Penco G, Sfara C, Madeddu G, Bonfanti P; for the CISAI study group. Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: Results from the SIMONE study. J Infect. 2008; 57: 33-40.